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BACKGROUND: Bevacizumab has been used in NSCLC in Europe since its regula-
tory approval in 2007. Bevacizumab has demonstrated significantly improved sur-
vival in randomized phase III trials. The real life outcomes have so far, however,
been assessed only in the US with evidence from routine clinical practice not
previously available in Europe. OBJECTIVES: To investigate Time to Progression
(TTP) in two pilot countries and thus assess the feasibility of such studies in awider
European setting. The primary comparison was bevacizumab-based therapy ver-
sus non-bevacizumab-based therapy in first-line non-squamous NSCLC.
METHODS:Datawere drawn from the Adelphi NSCLCDisease Specific Programme,
a large cross-sectional study of consecutively presenting patients in France and
Germany in 2010. Physicians provided retrospective information regarding disease
status and treatment patterns. TTP was defined as time from start of treatment to
physician-reported disease progression or two weeks before the start of second-
line therapy. A log rank test was applied to test for differences between the two
comparison groups. Cox Proportional Hazard Models were fitted to the data. Sen-
sitivity analyses were run to analyse if age was a prognostic factor for treatment
benefit between the two groups. RESULTS: A total of 895 non-squamous patients
were included in the analyses, of whom 421 had experienced disease progression.
The median time to progression for bevacizumab-treated patients was 8.5 months
compared with 6 months in the comparison group (p0.001). The Hazard ratio
relating to the treatment effect (bevacizumab-based versus non-bevacizumab
based) was 0.65 (95% CI 0.52 to 0.81). The differences in TTP remain significant
between the two first-line therapy groups even after controlling for age.
CONCLUSIONS: The feasibility of using real life oncology studies in Europe to dem-
onstrate extended TTP for bevacizumab-based versus non-bevacizumab therapy
was shown and was consistent with findings of two phase III trials and real life
outcomes from a US study.
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OBJECTIVES: The objective of this study, as part of the Center for Comparative
Effectiveness Research in Cancer Genomics (CANCERGEN), was to establish and
evaluate a process for incorporating formal value of research (VOR) analyses into a
stakeholder-informed research prioritization process for genomic applications for
study in a prospective, randomized comparative effectiveness trial within the
SWOG clinical trials cooperative. METHODS: Six candidate genomic applications,
identified through a landscape-analysis, were prioritized by 13 stakeholders based
on 9 criteria: population impact, adequacy of standard care, analytic and clinical
validity, benefits, harms, economic impact, evidence of need, clinical trial feasibil-
ity, and market factors. We developed decision-analytic based models for the top
three candidates, performed expected value of perfect information calculations,
and presented the results to stakeholders. We evaluated the impact of the VOR
analyses on the test ranking and stakeholder perceptions about the usefulness of
VOR using an online survey. RESULTS: The top three genomic applications based
on the initial rankings were: 1) ERCC1 testing in early stage non-small cell lung
cancer (NSCLC), 2) EGFRmutation testing in advanced NSCLC, and 3) tumormarker
testing to detect recurrence in early stage breast cancer (BC). The VOR was esti-
mated to be: $2.2 to $2.8 billion, $33 million, and $2.1 billion, respectively. After
presentation of the results, the stakeholders changed their ranking to 1) ERCC1, 2)
BC markers, and 3) EGFR. The majority of stakeholders found the VOR information
to be useful (69%), with 53% changing their ranking after consideration of the VOR
findings. In addition, all stakeholders indicated that they would use VOR analyses
in future research prioritization processes. CONCLUSIONS: Stakeholder-informed
research prioritization of genomic applications is a function of many evidence
domains. Our study suggests that with adequate resources, VOR analyses can be
incorporated into this process and provide useful information for research priori-
tization.
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OBJECTIVES: To assess the value of additional research for testing carcinoem-
broynic antigen (CEA), cancer antigen (CA)15-3 and CA 27.29 biomarkers for earlier
detection and treatment of recurrent breast cancer. METHODS: We developed a
decision-analytic model to estimate the expected value of perfect information
(EVPI) and expected value of sample information (EVSI) for a treatment strategy
involving biomarker testing every 3-6 months for the five years following comple-
tion of primary therapy (in addition to standard care), versus standard care alone.
Model parameters and uncertainty ranges were derived from published literature
and expert opinion. EVPI and EVSI were assessed at various willingness-to-pay
thresholds. The affected populationwas estimated frompublished recurrence data
over a discounted 10-year time horizon. RESULTS: At a willingness-to-pay of
$150,000 per quality-adjusted life year, the biomarker strategy and standard-care
strategy resulted in average net-benefits of $598,000 and $600,000, respectively.
The standard care strategy produced greater net-benefit in 57% of simulations.
Among the 43% of simulations where standard care produced greater net-benefit,
the average difference was $11,200. With an affected population of approximately
417,000 patients, the EVPI was $2.1 billion. Preliminary EVSI estimates range from
$36 to $76 million at sample sizes between 500 to 5,000 patients per arm,
respectively. CONCLUSIONS: Our findings indicate that research assessing the use
of breast cancer recurrence biomarkers and consequent earlier treatment could be
highly valuable. The EVPI of approximately $2.1 billion represents the upper bound
of the value of additional research, and is driven by the affected population, testing
sensitivity and specificity, costs, and uncertainty in the choice of optimal strategy.
We are currently conducting EVSI analyses for various trial designs, compared to
the cost of conducting these trials. Our analysis allows decision makers to quanti-
tatively assess and prioritize research efforts in biomarker testing for breast cancer
recurrence relative to alternative research investments.
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OBJECTIVES: Prostate cancer treatments are comparable in long-term outcome;
but associated with different health-related-quality-of-life (HRQOL) outcomes, in-
cluding erectile dysfunction(ED). We studied influence of changes in sexual func-
tion(SF) and bother(SB) on 3-monthly-ED cost over 13.5 years and estimated pre-
dictors of ED costs across and within treatments. METHODS: Data were from
CaPSURE, a national disease registry of 3,276 men with prostate cancer from 31
urology practices completing questionnaires including risk, healthcare utilization
and HRQOL. SF and SB scores(0-100) were measured by UCLA Prostate Cancer In-
dex. ED 2009 costs included drugs, vacuum erection devices and penile implants.
Bootstrapped regression models determined influence of age, BMI, race, marital
status, risk, baseline and changes in SF/SB scores, and co-morbidities on ED costs.
RESULTS: 62% had prostatectomy(RP), 48% were low-risk, and mean age was
64.3(64.1-64.6)years. Baseline SF score was 53.8(52.8-54.8) and SB 62.3(61-63.6).
Mean ED cost was highest for RP ($78.6;$71.1-$86.1), followed by Brachytherapy
($42.7;$30.8-$54.6), Radiation ($35.5;$18-$53) andwatchfulwaiting(WW)($25.5;$8.2-
$42.9). Increasing baseline SF ($0.61,p0.001), SF decline ($30,p0.001), 1co-mor-
bidity ($72,p0.001), treatment type (p0.01), increasing age (p0.07), being mar-
ried ($22,p0.002), and being non-white ($133,p0.001), significantly predicted ED
costs. RP had $42 significantly higher ED cost thanWWwhile Brachy and Radiation
had $15 more. Individuals 70 and older had $32 lower ED costs than 50year olds.
For WW, increasing age ($3,p0.05) and higher BMI ($42,p0.03) significantly pre-
dicted lower ED costs. For RP, higher baseline-SF ($0.66, p0.001), declining-SF
($48,p0.001), improved/no-change SB scores ($15,p0.05), 1co-morbidity
($93,p0.001), married ($34,p0.007), and non-white ($165,p0.001) significantly
predicted higher ED costs. For Brachytherapy, increasing baseline-SF
($0.42,p0.001) and for radiation, higher BMI ($32,p0.06) predicted higher ED
costs. CONCLUSIONS: Treatment type and age were strongest ED cost predictors
with the younger RP patients showing highest ED costs and the older WW group
with lowest ED costs. These results can guide physicians and patients deciding on
prostate cancer therapies.
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OBJECTIVES: To understand factors that impact therapeutic decisions and to un-
derstand healthcare resource utilization. METHODS: A modified Delphi panel
study was conducted, utilizing in-depth interviews with 16 CML-treating physi-
cians to develop key themes and questions for testing, followed by an on-line
survey to capture initial estimates. Results were discussed at a live meeting with 7
CML-treating physicians to develop consensus and complete another round of
surveying. RESULTS: The majority of panelists believe that 20-30% of patients are
not treated in accordance with CML guidelines. An estimated (mean) 25% of pa-
tients are switched from imatinib to nilotinib or dasatinib during the first year.
Community oncologists are more likely to switch treatment due to side effects,
whereas academic clinicians primarily switch for efficacy-related concerns. Six
panelists indicatedmajormolecular response (MMR) is a superior endpoint to com-
plete cytogenetic response (CCyR) with credible evidence to support that MMR
provides superior protection from progression. Panelists believe that molecular
monitoring is less intensive and less time-consuming and is a better predictor of
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